Maximising RWE Impact Across the Product Lifecycle to De-Risk Development & Elevate Market Access

• Use RWE to inform study design, feasibility, and decision-making to prevent costly delays and reduce early clinical delays
• Close evidence gaps before launch to secure smoother pricing and reimbursement pathways strengthening HTA readiness
• Deploy targeted RWE to demonstrate real-world value and support confident market entry.

Speakers:

Zeki Kocaata

Senior Director, Global Real World Evidence & Health Outcomes Lead Vaccines

GlaxoSmithKline